Kwality Pharmaceuticals: Kwality Pharmaceuticals Limited Secures EU-GMP Approval from Hungary for Cephalosporin and Oncology Facilities
Kwality Pharmaceuticals (KPL) filed a disclosure titled "Kwality Pharmaceuticals Limited Secures EU-GMP Approval from Hungary for Cephalosporin and Oncology Facilities". The company is valued at about ₹3,881 crore.
What happened
Kwality Pharmaceuticals (KPL) filed a disclosure with the exchanges on 4 November 2026 at 12:59 PM titled "Kwality Pharmaceuticals Limited Secures EU-GMP Approval from Hungary for Cephalosporin and Oncology Facilities".
Company snapshot
Kwality Pharmaceuticals is a small-cap company, with a market value of about ₹3,881 crore.
The stock last traded at ₹3,740.4, against a 52-week range of ₹1,561–₹3,949 (5.3% below the high).
Before this filing the shares had moved +1.9% over the month and +40.4% over three months. Average daily turnover over the last 20 sessions was about ₹9.89 crore.
Promoters held 54.86% at the end of Q1 FY27. Foreign institutions owned 3.13% and domestic institutions 0.56%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 111 | 11.9 | 11.5 |
| Q2 FY26 | 111 | 14.1 | 13.6 |
| Q3 FY26 | 123 | 16 | 15.43 |
| Q4 FY26 | 157 | 25.3 | 24.37 |
| Q1 FY27 | 162 | 25.6 | 24.7 |
What history shows
This is not the company's first approval disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.
Market-wide, 1,575 approval filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 48% rising.
Past reactions describe what happened before; they are not a forecast.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.